Erschienen in:
01.04.2011 | Review
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
verfasst von:
Stéphanie Gaillard, Vered Stearns
Erschienen in:
Breast Cancer Research
|
Ausgabe 2/2011
Einloggen, um Zugang zu erhalten
Abstract
Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone, bone and musculoskeletal side effects are substantial and often lead to discontinuation of therapy. Ideally, the symptoms should be prevented or adequately treated. This review will focus on bone and musculoskeletal side effects of aromatase inhibitors, including osteoporosis, fractures, and arthralgias. Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes.